|
| 33585852 | New up-conversion luminescence in molecular cyano-substituted naphthylsalophen lanthanide(iii) complexes. | Chem Commun (Camb) | 2021 |
| 29363356 | Sedative Plasma Concentrations and Delirium Risk in Critical Illness. | Ann Pharmacother | 2018 |
| 19239339 | Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. | J Infect Dis | 2009 |
| 19034106 | Tariquidar, a selective P-glycoprotein inhibitor, does not potentiate loperamide's opioid brain effects in humans despite full inhibition of lymphocyte P-glycoprotein. | Anesthesiology | 2008 |
| 17996661 | Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients. | Am J Geriatr Pharmacother | 2007 |
| 16537797 | Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier. | J Pharmacol Exp Ther | 2006 |
| 17047492 | Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. | Pharmacogenet Genomics | 2006 |
| 16952489 | The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. | Clin Pharmacol Ther | 2006 |
| 16912957 | Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. | Clin Infect Dis | 2006 |
| 16394685 | Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. | Anesthesiology | 2006 |
| 16392089 | Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. | Clin Infect Dis | 2006 |
| 16424822 | Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. | Pharmacogenet Genomics | 2006 |
| 15917386 | Drug metabolism and variability among patients in drug response. | N Engl J Med | 2005 |
| 16267764 | Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. | J Infect Dis | 2005 |
| 15102541 | Genetic variability in CYP3A5 and its possible consequences. | Pharmacogenomics | 2004 |
| 15622315 | Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. | AIDS | 2004 |
| 15289786 | Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. | Clin Pharmacol Ther | 2004 |
| 15470333 | In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. | Clin Pharmacol Ther | 2004 |
| 15116049 | CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. | Clin Pharmacol Ther | 2004 |
| 15070684 | 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. | Blood | 2004 |
| 12545142 | Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. | Clin Pharmacol Ther | 2003 |
| 14515058 | Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. | Pharmacogenetics | 2003 |
| 14600574 | MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. | J Acquir Immune Defic Syndr | 2003 |
| 14583845 | A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. | HIV Clin Trials | 2003 |
| 12621390 | Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. | Clin Pharmacol Ther | 2003 |
| 12814461 | Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. | Br J Clin Pharmacol | 2003 |
| 11936561 | Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. | J Clin Pharmacol | 2002 |
| 12235449 | Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans. | Clin Pharmacol Ther | 2002 |
| 12362920 | Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. | J Clin Pharmacol | 2002 |
| 11503014 | Identification of functionally variant MDR1 alleles among European Americans and African Americans. | Clin Pharmacol Ther | 2001 |
| 11372001 | CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. | Clin Pharmacol Ther | 2001 |
| 11740342 | In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. | Pharmacogenetics | 2001 |
| 11459203 | In vivo inhibition of human CYP1A2 activity by oltipraz. | Cancer Chemother Pharmacol | 2001 |
| 11455026 | Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. | Mol Pharmacol | 2001 |
| 10820137 | Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. | Drug Metab Dispos | 2000 |
| 10945319 | CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. | Clin Pharmacol Ther | 2000 |
| 11054262 | Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. | AIDS Res Hum Retroviruses | 2000 |
| 10510153 | Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. | Br J Clin Pharmacol | 1999 |
| 10463589 | P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. | Cancer Res | 1999 |
| 10411572 | A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. | J Pharmacol Exp Ther | 1999 |
| 10385138 | Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. | Cancer Epidemiol Biomarkers Prev | 1999 |
| 10213372 | Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. | Pharm Res | 1999 |
| 10421612 | OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. | Drug Metab Dispos | 1999 |
| 10190659 | Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. | Br J Clin Pharmacol | 1999 |
| 9889399 | Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. | Biochim Biophys Acta | 1999 |
| 9927403 | Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. | Circulation | 1999 |
| 10591534 | Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. | Pharmacogenetics | 1999 |
| 10634132 | Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. | Pharmacogenetics | 1999 |
| 10613613 | Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. | Clin Pharmacol Ther | 1999 |
| 10565843 | Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. | J Pharmacol Exp Ther | 1999 |